Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the June 16, 2025 deadline to become a lead plaintiff in a securities class action lawsuit related to the company's September 2024 IPO [1][5]. Group 1: Legal Action Details - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 16, 2025 [3]. - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding the company's financial sustainability and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them for discussions regarding their legal rights [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to reach out to the firm [6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [2]. IPO Details - The company conducted its IPO on September 13, 2024, selling over 13 million shares at a price of $17.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false and misleading, specifically overstating the duration Zenas BioPharma could fund its operations with existing cash and expected IPO proceeds [3]. - It was later revealed that Zenas BioPharma could only fund its operations for 12 months instead of the 24 months previously stated in the IPO registration [4]. Stock Performance - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, which is 48.7% lower than the IPO price [4]. Legal Process - Investors who purchased Zenas BioPharma securities can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased or acquired Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost or obligation to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product candidate acquisition strategy to identify and develop therapies that provide superior clinical benefits to patients [3] Upcoming Events - Zenas BioPharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET [1] - A live webcast and archived replay of the presentation will be available on the company's website under the "Events and Presentations" section [2]

Core Viewpoint - A class action lawsuit has been filed against Zenas Biopharma, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Zenas Biopharma overstated the sustainability of its operations based on existing cash and expected IPO proceeds, leading to false and misleading public statements during the IPO period [2]. - Investors who purchased securities linked to the IPO on September 13, 2024, are encouraged to contact the law firm before June 16, 2025, to participate in the lawsuit [1][2]. Group 2: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [3]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO, particularly regarding the company's financial sustainability and operational funding timeline [1][2]. Group 1: Allegations and Financial Misrepresentation - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations, claiming it could sustain operations for twenty-four months instead of the actual twelve months as disclosed in its Form 10-Q filed on November 12, 2024 [2]. - Following the revelation of these material adverse facts, Zenas BioPharma's stock price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 16, 2025, while those who choose not to participate can remain as absent class members [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to opt for passive involvement [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]. - The firm has a history of advocating for shareholder rights and aims to hold company executives accountable for their actions [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc., and it allows purchasers of Zenas BioPharma securities from the IPO to seek lead plaintiff status until June 16, 2025 [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock price was $8.72, which is 48.7% lower than the IPO price of $17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares during its IPO at a price of $17.00 per share [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding Zenas BioPharma's financial situation, specifically overstating the duration it could fund operations with existing cash and IPO proceeds [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].